Aethlon Medical
San Diego, United States · Biotechnology, Health Care, Medical · 24 employees
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has pote
Funding history
- Funding Round — $2.2M — Dec 2025
- Funding Round — $2.7M — Jan 2020
- Funding Round — $6.0M — Jul 2015
Recent signals
- Dec 23, 2025: Raised $2.2M
- Nov 06, 2025: SEC 8-K (5.02): On November 5, 2025, Aethlon Medical, Inc. received notification from the Nasdaq Listing Qualifications Department confirming that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. This follows a prior notification on October 16, 2025, regarding a non-compliance issue where the company's common stock had closed below the $1.00 minimum for 30 consecutive business days. Regaining compliance signifies the company's ability to continue its trading on Nasdaq, which is crucial for maintaining investor confidence and access to capital. The event demonstrates operational recovery and strategic importance for Aethlon Medical, Inc.
- Oct 03, 2024: Aethlon Medical Elevates James B. Frakes to Permanent Chief Executive Officer
- Nov 13, 2023: Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer
- Jan 24, 2020: Raised $2.7M
- Jul 09, 2015: Raised $6.0M
See plans & pricing → Track Aethlon Medical’s funding, hiring, and signals — with verified contacts — on Fundz.